Going back to Tarceva from Tagrisso?
Forums
March 18, 2018 at 1:24 am #1294108
- Read more about Going back to Tarceva from Tagrisso?
- Log in or register to post comments
Tarceva and ammonia levels
Forums
Has there been any correlation between taking Tarceva and increased in blood ammonia levels? I have a sister, age 61 who has vulvar cancer stage IV and she recently started taking Tarceva as of January 21st. She was sent to the ER for possible stroke but that has been ruled out. Only abnormal was her ammonia level.
- Read more about Tarceva and ammonia levels
- 1 comment
- Log in or register to post comments
Translation of Molecular Genetics in Lung Cancer into Treatment Decision
Article
- Christine M. Walko, Pharm.D., discusses how advancements in technology have improved the quality, cost and turnaround time for assessing genetic mutations in tumor tissue, and how this has helped to translate precision medicine into standard clinical practice.
Maintenance Therapy for Advanced NSCLC
Video
Dr. Jack West, Swedish Cancer Institute, defines maintenance therapy in advanced NSCLC and discusses maintenance treatment strategies.
Combinations and Other Options for Acquired Resistance in EGFR Mutation-Positive NSCLC
Video
Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a combination of Gilotrif and Erbitux.
Third Generation EGFR TKIs for Acquired Resistance
Video
Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.
Targeted Therapies in a Post-Operative/Adjuvant Setting
Video
Dr. Nathan Pennell, Cleveland Clinic, reviews the available trial evidence for the use of targeted therapies in the post-operative/adjuvant setting.
Emerging Options for T790M-Positive Acquired Resistance
Video
Acquired resistance in EGFR patients is often driven by the T790M mutation. T790M-positive tumors respond differently to treatments than T790M-negative tumors. Dr. Greg Riely details how each status can predict patients' responses to current treatments.
Does the Specific EGFR Mutation (Including "Rare" Mutations) Matter When Choosing an Oral EGFR Inhibitor?
Article
Drs. Leora Horn, Ben Solomon, & Jack West discuss the open question of whether there are clinically significant differences among leading EGFR tyrosine kinases based on the specific EGFR mutation to be treated.
First Line Treatment of EGFR Mutation-Positive NSCLC
Article
MSKCC medical oncologist Dr. Greg Riely reviews the optimal first line treatment of patients with an EGFR mutation-positive advanced lung cancer.